AAIP logo

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022

Summary

What is already known about this topic?

CDC recommended bivalent COVID-19 booster vaccination for persons aged ≥12 years in August 2022; approximately 22.6 million bivalent booster doses were administered during August 31–October 23, 2022.

What is added by this report?

Early safety findings from v-safe and the Vaccine Adverse Event Reporting System for bivalent booster doses administered to persons aged ≥12 years during the first 7 weeks of vaccine availability are similar to those previously described for monovalent vaccine booster vaccines.

What are the implications for public health practice?

Adverse events reported after a bivalent booster dose appear consistent with those reported after a monovalent booster and are less common and less serious than health impacts associated with COVID-19 illness.

Read more here

Skip to content